| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
157.30(B) |
| Last
Volume: |
3,063,631 |
Avg
Vol: |
8,386,047 |
| 52
Week Range: |
$89.14 - $128.07 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 425 |
| Guru Rank Value : 4.8 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
115,146 |
191,646 |
797,076 |
1,093,743 |
| Total Sell Value |
$14,012,300 |
$22,773,006 |
$82,029,846 |
$108,272,603 |
| Total People Sold |
4 |
5 |
5 |
6 |
| Total Sell Transactions |
9 |
19 |
31 |
46 |
| End Date |
2025-08-31 |
2025-05-30 |
2024-11-29 |
2023-11-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Dickinson Andrew D |
Chief Financial Officer |
|
2025-11-17 |
4 |
AS |
$125.23 |
$313,075 |
D/D |
(2,500) |
154,555 |
|
1% |
|
Mercier Johanna |
Chief Commercial Officer |
|
2025-11-17 |
4 |
AS |
$125.83 |
$3,524,173 |
D/D |
(28,000) |
107,193 |
|
1% |
|
Mercier Johanna |
Chief Commercial Officer |
|
2025-11-17 |
4 |
OE |
$66.64 |
$1,666,000 |
D/D |
25,000 |
135,193 |
|
- |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2025-11-12 |
4 |
AS |
$122.30 |
$6,590,487 |
D/D |
(53,646) |
43,676 |
|
2% |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2025-11-12 |
4 |
OE |
$60.75 |
$3,505,885 |
D/D |
53,646 |
44,176 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2025-10-28 |
4 |
AS |
$118.82 |
$1,193,926 |
D/D |
(10,000) |
581,203 |
|
7% |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2025-10-25 |
4 |
D |
$120.94 |
$29,147 |
D/D |
(241) |
43,676 |
|
- |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2025-10-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
515 |
43,917 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2025-10-15 |
4 |
AS |
$118.08 |
$295,200 |
D/D |
(2,500) |
157,055 |
|
6% |
|
Mercier Johanna |
Chief Commercial Officer |
|
2025-10-15 |
4 |
AS |
$118.08 |
$354,240 |
D/D |
(3,000) |
110,193 |
|
6% |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2025-09-29 |
4 |
AS |
$111.47 |
$1,116,564 |
D/D |
(10,000) |
591,203 |
|
12% |
|
Mercier Johanna |
Chief Commercial Officer |
|
2025-09-15 |
4 |
AS |
$113.57 |
$340,710 |
D/D |
(3,000) |
113,193 |
|
12% |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2025-09-15 |
4 |
AS |
$113.57 |
$283,925 |
D/D |
(2,500) |
159,555 |
|
12% |
|
Wilfong Diane E |
Interim Corp Controller & CAO |
|
2025-09-10 |
4 |
D |
$115.25 |
$38,955 |
D/D |
(338) |
46,259 |
|
- |
|
Wilfong Diane E |
Interim Corp Controller & CAO |
|
2025-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
921 |
46,597 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2025-09-10 |
4 |
D |
$115.25 |
$570,372 |
D/D |
(4,949) |
601,203 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2025-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,427 |
606,152 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2025-09-10 |
4 |
D |
$115.25 |
$201,803 |
D/D |
(1,751) |
162,055 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2025-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,696 |
163,806 |
|
- |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2025-09-10 |
4 |
D |
$115.25 |
$73,069 |
D/D |
(634) |
43,402 |
|
- |
|
Telman Deborah H |
EVP, Corporate Affairs & GC |
|
2025-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,315 |
44,036 |
|
- |
|
Mercier Johanna |
Chief Commercial Officer |
|
2025-09-10 |
4 |
D |
$115.25 |
$209,640 |
D/D |
(1,819) |
116,193 |
|
- |
|
Mercier Johanna |
Chief Commercial Officer |
|
2025-09-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,844 |
118,012 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2025-08-28 |
4 |
AS |
$113.63 |
$1,136,300 |
D/D |
(10,000) |
595,725 |
|
12% |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2025-08-15 |
4 |
AS |
$118.53 |
$296,325 |
D/D |
(2,500) |
160,110 |
|
6% |
|
924 Records found
|
|
Page 1 of 37 |
|
|